BioCryst Pharmaceuticals BCRX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Collaborative and other revenues | $7.96M+26.2% | $7.71M-4.2% | $6.52M-23.4% | $5.88M-34.3% | $6.3M-34.3% | |
| ORLADEYO | $615.94M+27.5% | $601.84M+37.5% | $574.34M+42.0% | $531.59M+42.2% | $483.04M+39.4% | |
| Other revenues | $22.78M+11.4% | $29.02M+122% | $25.47M+210% | $25.92M+204% | $20.45M+128% | |
| Product sales, net | $630.77M+26.9% | $623.15M+40.8% | $593.3M+46.8% | $551.63M+47.8% | $497.18M+43.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BioCryst Pharmaceuticals break its business down?
- BioCryst Pharmaceuticals (BCRX) reports total revenues by product across 5 parts — Collaborative and other revenues, License and other revenues, ORLADEYO, Other revenues and Product sales, net. Each is extracted from the segment footnotes and tracked over time.
- Where does BioCryst Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioCryst Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
